AbbVie Inc. (ABBV): EPS (Diluted)
$2.36
Year ended 2025-12-31
-29.1%
3-year compound annual growth
-2.8%
5-year compound annual growth
-2.8%
10-year compound annual growth
| Period ended | EPS (Diluted) | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $2.36 | -1.3% | 2026-02-20, From 2025-01-01 |
| 2024-12-31 | $2.39 | -12.1% | 2026-02-20, From 2024-01-01 |
| 2023-12-31 | $2.72 | -59.0% | 2026-02-20, From 2023-01-01 |
| 2022-12-31 | $6.63 | +2.8% | 2025-02-14, From 2022-01-01 |
| 2021-12-31 | $6.45 | +137.1% | 2024-02-20, From 2021-01-01 |
| 2020-12-31 | $2.72 | -48.5% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $5.28 | +44.3% | 2022-02-18, From 2019-01-01 |
| 2018-12-31 | $3.66 | +10.9% | 2021-02-19, From 2018-01-01 |
| 2017-12-31 | $3.30 | -9.1% | 2020-02-21, From 2017-01-01 |
| 2016-12-31 | $3.63 | +16.0% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $3.13 | +184.5% | 2018-02-16, From 2015-01-01 |
| 2014-12-31 | $1.10 | -57.0% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $2.56 | -23.6% | 2016-02-19, From 2013-01-01 |
| 2012-12-31 | $3.35 | +53.7% | 2015-02-20, From 2012-01-01 |
| 2011-12-31 | $2.18 | n/a | 2014-02-21, From 2011-01-01 |
EPS (Diluted) at similar companies
| Company | Year ended | EPS (Diluted) | Change YoY |
|---|---|---|---|
| AbbVie Inc. (ABBV) | 2025-12-31 | $2.36 | -1.3% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.36 | -3.5% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $7.28 | +8.0% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $22.95 | +96.0% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $3.46 | n/m |
| Abbott Laboratories (ABT) | 2025-12-31 | $3.72 | -51.3% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $11.03 | +90.5% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $1.21 | n/m |
| Regeneron Pharmaceuticals, Inc. (REGN) | 2025-12-31 | $41.48 | +8.2% |
Compare ABBV, PFE, MRK, LLY side by side · Screen every company in Pharmaceutical Preparations ↗